Mebendazole: Clinical Evidence & Trials
Mebendazole is an antiparasitic medication used to treat intestinal worms, tissue parasites, or ectoparasitic infections.
Benzimidazoles are WHO essential medicines with strong evidence for soil-transmitted helminthiasis, echinococcosis, and neurocysticercosis.
Evidence Strength
Level A (Strong) for soil-transmitted helminthiasis (ascariasis, enterobiasis, trichuriasis); Level B for echinococcosis and neurocysticercosis (combined with praziquantel/corticosteroids).
Key Clinical Trial Findings
- •WHO MDA programmes — albendazole/mebendazole mass drug administration in school-age children achieves >90% cure rates for Ascaris, >85% for hookworm
- •Cochrane review (Taylor-Robinson 2019) — single-dose albendazole vs placebo: cure rate 97% for Ascaris lumbricoides, ~88% for hookworm
- •Echinococcosis — PAIR (puncture-aspiration-injection-reaspiration) + albendazole superior to surgery alone; albendazole reduces cyst recurrence (NEJM 2000 WHO trial)
- •Neurocysticercosis — cysticidal albendazole + dexamethasone reduces seizure recurrence (Del Brutto Cochrane 2014; Lancet Neurology meta-analysis)
- •Enterobiasis — single-dose mebendazole 100mg or albendazole 400mg: >95% cure rate; family treatment recommended
Numbers Needed to Treat (NNT)
Ascariasis (single dose): NNT ≈ 1.1 for parasite clearance. Echinococcosis (adjuvant to PAIR): NNT ≈ 3 for recurrence prevention. Preventive chemotherapy in endemic school children: NNT ≈ 6 for anaemia prevention.
Guideline Recommendations
WHO Essential Medicines List: both albendazole and mebendazole included. WHO recommends annual/biannual MDA for STH in endemic areas. NICE: mebendazole first-line for threadworm in UK. CDC: albendazole first-line for echinococcosis, neurocysticercosis, and alternative for giardiasis.
Conditions Treated with Mebendazole
Questions about your medication?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant medications.
Use AI Symptom Checker →